No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Hong Kong stocks movement | IMMUNEONCO-B (01541) surged over 18% in the morning, with annual revenue increasing 192 times year-on-year. Institutions claim the company's current value is severely underestimated.
IMMUNEONCO-B (01541) rose nearly 18% in the morning session, as of the time of writing, the increase is 18.66%, trading at 6.93 Hong Kong dollars, with a transaction amount of 25.4688 million Hong Kong dollars.
Hong Kong stocks are fluctuating | Pharmaceutical stocks are strong in the morning, domestic Innovative Drugs are gradually entering the harvest period, and the market anticipates optimization of the central procurement policy.
Pharmaceutical stocks strengthened in the morning session. As of the time of publication, IMMUNEONCO-B (01541) rose by 17.64% to HKD 6.87; AKESO (09926) increased by 15.49% to HKD 88; and REMEGEN (09995) climbed by 11.18% to HKD 26.35.
IMMUNEONCO-B (01541.HK): Core pipeline is steadily advancing and actively expanding BD collaboration.
Event: On March 25, 2025, Yiming Anke released the 2024 annual performance report, achieving total revenue of 74.15 million yuan for the year (mainly from licensing fees and cooperative development income), a year-on-year growth of 192 times.
The Chairman and CEO of Yiming Anke (01541.HK) increased their shareholding by 0.15 million shares, involving 0.79 million yuan.
IMMUNEONCO-B (01541.HK) announced that Executive Director, Chief Executive Officer, and Chairman of the Board of Directors Tian Wenzhi purchased a total of 150,000 shares of the company's H shares on the open market on Wednesday (the 26th) at an average price of approximately 5.278 yuan per share, accounting for about 0.04% of the company's total issued shares. The estimated transaction involved about 791,700 yuan. Following the purchase, Tian Wenzhi owns equity in a total of 0.116 billion shares, accounting for 28.49% of the company's total issued capital.
IMMUNEONCO-B (01541) is acquiring 0.15 million shares of Listed in Hong Kong by Chief Executive Officer Tian Wenzhi.
IMMUNEONCO-B (01541) announced that the company's Board of Directors received a report from the company's executive director, chief executive officer, and the board...
ImmuneOnco Biopharmaceuticals Shrinks Loss in 2024
